Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005

Trial Profile

Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 Aug 2014 Planned End Date changed from 1 Aug 2018 to 1 Oct 2022 as reported by ClinicalTrials.gov record.
    • 09 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Additional location (Belgium) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top